C-反应蛋白是转移性胃癌的一个潜在预后因素。
C-reactive protein is a potential prognostic factor for metastatic gastric cancer.
机构信息
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
出版信息
Anticancer Res. 2012 Feb;32(2):491-6.
BACKGROUND/AIM: C-reactive protein (CRP) has been associated with the development of many carcinomas, but the significance of CRP remains unclear for metastatic gastric cancer (MGC).
PATIENTS AND METHODS
Sixty one patients who received S-1 plus cisplatin for MGC were retrospectively identified and categorized into two groups depending on the serum CRP level before chemotherapy.
RESULTS
Overall survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 292 days versus 451 days; p=0.0004). Moreover, progression-free survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 115 days versus 188 days; p=0.0010). In a multivariate analysis, serum CRP level before chemotherapy was an independent prognostic factor for MGC (hazard ratio 4.20 [95% CI, 1.66 to 10.64] p=0.002).
CONCLUSION
Serum CRP level before chemotherapy might be a potential prognostic factor for MGC.
背景/目的：C 反应蛋白（CRP）与许多癌症的发生有关，但 CRP 对转移性胃癌（MGC）的意义尚不清楚。
患者和方法
回顾性分析了 61 例接受 S-1 联合顺铂治疗的 MGC 患者，并根据化疗前血清 CRP 水平将其分为两组。
结果
CRP≥1.0 组的总生存期明显短于 CRP<1.0 组（中位生存期 292 天 vs 451 天；p=0.0004）。此外，CRP≥1.0 组的无进展生存期明显短于 CRP<1.0 组（中位生存期 115 天 vs 188 天；p=0.0010）。多因素分析显示，化疗前血清 CRP 水平是 MGC 的独立预后因素（危险比 4.20[95%CI，1.66 至 10.64]，p=0.002）。
结论
化疗前血清 CRP 水平可能是 MGC 的一个潜在预后因素。
Zotero 插件